The company’ share price has doubled since the start of 2017, last trading at $0.046.
EndoBarrier is an endoscopically delivered device therapy for the treatment of type 2 diabetes and obesity.
GI Dynamics conducted the study at the University Children’s Hospital (UCH) in Ljubljana, Slovenia.
The study was designed to determine the efficacy and safety of the EndoBarrier treatment for up to one year in morbidly obese adolescents.
Preliminary data show that patients who received the treatment saw an average of 10% decrease in body mass index (BMI) and metabolic improvements.
EndoBarrier demonstrated therapeutic benefit in treating prediabetes, as blood sugar levels were reduced by 6%.
Most notable was the 49% improvement in HOMA-IR (Homeostatic Model Assessment), a critical measure of insulin resistance and beta-cell function.
EndoBarrier demonstrated an acceptable safety profile, with all study subjects completing treatment to the intended twelve-month implant duration.
Obesity and its complications have a significant effect on morbidity and mortality for adolescents.
Standard treatment-based diets and cognitive therapy have limited effects. Surgical bariatric procedures are non-reversible and permanently alter certain metabolic functions.
EndoBarrier is less invasive than surgery and can be inserted in a quick outpatient endoscopic procedure that patients are likely to find more acceptable.
GI Dynamics is well funded with a cash balance of $8.3 million as at 31 December 2016.